Abhijith Anand
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Abhijith Anand has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Magno Queiroz
College of Business, Florida Atlantic University, Boca Raton, FL, USA
2 shared publications - Aaron Baird
Department of Computer Information Systems, Colorado State University
1 shared publication - Paul P. Tallon
Loyola University Maryland
1 shared publication Rajeev Sharma
Waikato Management School, University of Waikato, Hillcrest, Hamilton 3240, New Zealand
1 shared publication- Rajeev Sharma
Deakin Business School, Deakin University, Victoria, Australia
1 shared publication - Rajeev Sharma
Affiliation Waikato Management School, University of Waikato, Hamilton, Waikato, New Zealand
1 shared publication
Latest Publications
- 19 June 2025
- Published by Taylor & Francis in European Journal of Information Systems
- Vol. 34 (6) , 1043-1065
IT resource relatedness and the search for agility: a complementarity perspective
- 19 June 2025
- Published by Taylor & Francis in European Journal of Information Systems
- Vol. 34 (6) , 1043-1065
IT resource relatedness and the search for agility: a complementarity perspective
- 2 July 2024
- Published by Taylor & Francis in Journal of Management Information Systems
- Vol. 41 (3) , 682-707
Manager Appraisal of Artificial Intelligence Investments
- 2 July 2024
- Published by Taylor & Francis in Journal of Management Information Systems
- Vol. 41 (3) , 682-707
Manager Appraisal of Artificial Intelligence Investments
- Open Access
- 5 April 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (4) , e0266271
The effect of pandemic prevalence on the reported efficacy of SARS-CoV-2 vaccines
The efficacy of SARS-CoV-2 vaccines reported in Phase 3 trials varies from ~45% to ~95%. This study tests the hypothesis that the observed variation in efficacy of SARS-CoV-2 vaccine candidates can be explained by the prevalence of the COVID-19 pandemic at trial sites. To test the proposed hypothesis, we conducted a systematic search following PRISMA guidelines. Our search resulted in 8 vaccine candidates that had reported efficacy data from a total of 20 Phase 3 trials, representing a total of 221,968 subjects, 453 infections across the vaccinated groups and 1,554 infections across the placebo groups. We use meta-regression models to analyse the potential associations between prevalence of COVID-19 pandemic at trial sites and efficacy of the reported SARS-CoV2 vaccines. The overall estimate of the risk-ratio is 0.24 (95% CI, 0.17–0.34, p ≤ 0.01), with a high degree of heterogeneity (τ2 = 0.50, I2 = 88.73%). Our meta-regression analysis with pandemic prevalence as the predictor explains almost half the variance in risk ratios across trials (R2 = 49.06%, p ≤ 0.01). This study finds that efficacy of SARS-CoV-2 vaccines reported in Phase 3 trial declines as pandemic prevalence at trial sites increases. Trials conducted in locations with low pandemic prevalence reported higher efficacies as compared to trials conducted in high pandemic prevalence locations.
- 5 April 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (4) , e0266271
Open AccessThe effect of pandemic prevalence on the reported efficacy of SARS-CoV-2 vaccines
The efficacy of SARS-CoV-2 vaccines reported in Phase 3 trials varies from ~45% to ~95%. This study tests the hypothesis that the observed variation in efficacy of SARS-CoV-2 vaccine candidates can be explained by the prevalence of the COVID-19 pandemic at trial sites. To test the proposed hypothesis, we conducted a systematic search following PRISMA guidelines. Our search resulted in 8 vaccine candidates that had reported efficacy data from a total of 20 Phase 3 trials, representing a total of 221,968 subjects, 453 infections across the vaccinated groups and 1,554 infections across the placebo groups. We use meta-regression models to analyse the potential associations between prevalence of COVID-19 pandemic at trial sites and efficacy of the reported SARS-CoV2 vaccines. The overall estimate of the risk-ratio is 0.24 (95% CI, 0.17–0.34, p ≤ 0.01), with a high degree of heterogeneity (τ2 = 0.50, I2 = 88.73%). Our meta-regression analysis with pandemic prevalence as the predictor explains almost half the variance in risk ratios across trials (R2 = 49.06%, p ≤ 0.01). This study finds that efficacy of SARS-CoV-2 vaccines reported in Phase 3 trial declines as pandemic prevalence at trial sites increases. Trials conducted in locations with low pandemic prevalence reported higher efficacies as compared to trials conducted in high pandemic prevalence locations.
- 1 December 2020
- Published by Institute for Operations Research and the Management Sciences (INFORMS) in Information Systems Research
- Vol. 31 (4) , 1144-1163
The Effects of Operational and Financial Performance Failure on BI&A-Enabled Search Behaviors: A Theory of Performance-Driven Search
For Practice and Policy Investments in business intelligence and analytics (BI&A) systems has grown exponentially in recent years. A key reason behind those investments is driven by the expectation that such investments e... about conditions under which firms leverage BI&A systems. Findings from this study suggest that firms employ BI&A systems only under a narrow set of conditions. Specifically, it is observed that BI... Business intelligence and analytics (BI&A) systems enable firms to analyze data and search for insights that could potentially lead to improved organizational performance. While there is evidence t...
- 1 December 2020
- Published by Institute for Operations Research and the Management Sciences (INFORMS) in Information Systems Research
- Vol. 31 (4) , 1144-1163
The Effects of Operational and Financial Performance Failure on BI&A-Enabled Search Behaviors: A Theory of Performance-Driven Search
For Practice and Policy Investments in business intelligence and analytics (BI&A) systems has grown exponentially in recent years. A key reason behind those investments is driven by the expectation that such investments e... about conditions under which firms leverage BI&A systems. Findings from this study suggest that firms employ BI&A systems only under a narrow set of conditions. Specifically, it is observed that BI... Business intelligence and analytics (BI&A) systems enable firms to analyze data and search for insights that could potentially lead to improved organizational performance. While there is evidence t...